• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Quantitative ELISA sandwich for a new vaccine against avian influenza virus H5N1

tetano

Editor, Senior Moderator
J Immunol Methods. 2018 May 24. pii: S0022-1759(17)30554-9. doi: 10.1016/j.jim.2018.05.008. [Epub ahead of print]
[h=1]Quantitative ELISA sandwich for a new vaccine against avian influenza virus H5N1.[/h] Pose AG[SUP]1[/SUP], Rodr?guez ER[SUP]2[/SUP], Pi?eiro MJ[SUP]2[/SUP], Montesino R[SUP]3[/SUP], S?nchez O[SUP]4[/SUP], Toledo JR[SUP]3[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Analytical techniques are essential in the process of standardizing and validating vaccines. In this study we described a methodology to establish an ELISA sandwich for the quantification of a new vaccine against avian influenza virus H5N1 based on the main antigenic determinant of the virus, the extracellular domain of the glycoprotein hemagglutinin, fused to the extracellular domain of the chicken CD154 glycoprotein. The chimerical proteins HA and HACD were produced in SiHa cells and the experiments were performed by using three monoclonal antibodies (MAb-HA1, MAb-HA2 and MAb-HA3), alone or conjugated to horseradish peroxidase (HRP-HA1, HRP-HA2 and HRP-HA3). The hemagglutination inhibition assay was carried out with a negative and a positive H5N2 reference serum, together with the antigen H5N1 A/Mallard/Italy/3401/05, all purchased from the "Istituto Zooprofilattico delle Venezie", Italy. After demonstrating the similar recognition pattern between the HA and the HACD proteins, the MAb-HA2 at a concentration of 2,5 μg/mL was selected as the capture antibody and the HRP-HA3 at a dilution of 1/20000 was selected as the detection antibody due to their optimal parameters at these conditions. The best dynamic range of the standard curve using the protein HACD was achieved at concentrations from 100 to 1,56 ng/mL. There were no significant differences when five batches of HACD were quantified by the ELISA sandwich and the bicinchoninic acid method linked to densitometry. In conclusion, the final parameters for the quantification of the chimeric protein HACD using an ELISA sandwich are described, which can contribute to develop a large-scale process for the final vaccine production.


[h=4]KEYWORDS:[/h] Avian influenza virus; CD154; ELISA sandwich; H5N1; Hemagglutinin

PMID: 29803776 DOI: 10.1016/j.jim.2018.05.008
 
Back
Top Bottom